THURSDAY, Sept. 11, 2024 -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been...
Vous n'êtes pas connecté
Lilly’s Kisunla Approved to Treat Early Symptomatic Alzheimer's Disease In July, the FDA cleared Eli Lilly’s Kisunla (donanemab-azbt), an amyloid beta-directed monoclonal antibody indicated for the treatment of early symptomatic...
THURSDAY, Sept. 11, 2024 -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been...
A new study published in the journal Brain reveals that increasing levels of a key brain protein might help slow cognitive decline in Alzheimer’s...
A team of researchers in Japan has discovered a potential new way to treat Alzheimer’s disease using dopamine, a chemical naturally produced in the...
A team of researchers in Japan has discovered a potential new way to treat Alzheimer’s disease using dopamine, a chemical naturally produced in the...
WEDNESDAY, Sept. 4, 2024 -- The humanized monoclonal antibody directed against the pituitary adenylate cyclase-activating polypeptide (PACAP) ligand,...
US drug giant also formally opens $800m expansion of obesity and diabetes medicines plant in Cork
A new study suggests that older adults who are more vulnerable to financial scams may have early brain changes linked to Alzheimer’s disease....
Eli Lilly stock boasts both defensive and growth characteristics
A monoclonal antibody appears effective at neutralizing the numerous variants of SARS-CoV-2, as well as related viruses in animals that could pose a...
New research has found a way to diagnose Alzheimer’s disease (AD) earlier by analyzing biomarkers in blood. This could help reduce the effects of...